Compare Akamai Technologies, Inc. (AKAM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Akamai Technologies, Inc. vs Sana Biotechnology Inc — how do they compare? Akamai Technologies, Inc. trades at $123.25 (market cap $16.77B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Akamai Technologies, Inc. is far larger — about 14.8× Sana Biotechnology Inc's market cap, and Akamai Technologies, Inc. is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| AKAM | SANA | |
|---|---|---|
Market Cap | $16.77B | $1.13B |
Sector | Technology | Health |
52-Week High | $161.14 | $5.92 |
52-Week Low | $71.97 | $2.68 |
Enterprise Value | $22.75B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $122.67, up 4.27% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with $4.21B revenue and 57.45% gross margins. Recent analyst upgrades and a $600M cloud contract highlight growth potential in AI and cybersecurity services.
Outlook remains cautiously optimistic with a $150.11 consensus price target offering 22% upside, though margin compression and competitive pressures present risks. Institutional sentiment leans neutral with 49% hold ratings, requiring monitoring of Q3 earnings execution and infrastructure investment returns.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
